{"title":"让免疫肿瘤学的火焰继续燃烧","authors":"","doi":"10.1038/d41573-025-00107-w","DOIUrl":null,"url":null,"abstract":"Ira Mellman, the new president of research at the Parker Institute for Cancer Immunotherapy, asks why so many drug developers are retreating from immune-modulating drugs, cell therapies and cancer vaccines before these modalities have achieved their full potential.","PeriodicalId":18847,"journal":{"name":"Nature Reviews Drug Discovery","volume":"64 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2025-06-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Keeping the immuno-oncology flame burning\",\"authors\":\"\",\"doi\":\"10.1038/d41573-025-00107-w\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Ira Mellman, the new president of research at the Parker Institute for Cancer Immunotherapy, asks why so many drug developers are retreating from immune-modulating drugs, cell therapies and cancer vaccines before these modalities have achieved their full potential.\",\"PeriodicalId\":18847,\"journal\":{\"name\":\"Nature Reviews Drug Discovery\",\"volume\":\"64 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2025-06-13\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Nature Reviews Drug Discovery\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1038/d41573-025-00107-w\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Nature Reviews Drug Discovery","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1038/d41573-025-00107-w","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
摘要
帕克癌症免疫治疗研究所（Parker Institute for Cancer Immunotherapy）的新任研究部主任Ira Mellman问道，为什么这么多的药物开发人员在免疫调节药物、细胞疗法和癌症疫苗尚未充分发挥其潜力之前就退出了这些领域。
Ira Mellman, the new president of research at the Parker Institute for Cancer Immunotherapy, asks why so many drug developers are retreating from immune-modulating drugs, cell therapies and cancer vaccines before these modalities have achieved their full potential.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
